K. K. Matthay

818 total citations
26 papers, 630 citations indexed

About

K. K. Matthay is a scholar working on Neurology, Cancer Research and Molecular Biology. According to data from OpenAlex, K. K. Matthay has authored 26 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Neurology, 10 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in K. K. Matthay's work include Neuroblastoma Research and Treatments (20 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Cancer therapeutics and mechanisms (8 papers). K. K. Matthay is often cited by papers focused on Neuroblastoma Research and Treatments (20 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Cancer therapeutics and mechanisms (8 papers). K. K. Matthay collaborates with scholars based in United States, United Kingdom and Australia. K. K. Matthay's co-authors include Robert C. Seeger, C. Patrick Reynolds, Judith G. Villablanca, Norma K.C. Ramsay, Aamir Ali Khan, Vassilios I. Avramis, Seymour Zoger, Peggy Reynolds, Steve Selvin and Joseph L. Wiemels and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and The Journal of Urology.

In The Last Decade

K. K. Matthay

26 papers receiving 617 citations

Peers

K. K. Matthay
Judith K. Sato United States
Rebecca Deyell Canada
J.C. Gentet France
M. Tezer Kutluk Türkiye
J. M. Zucker France
Aurora Medina‐Sansón Mexico
F. Breatnach Ireland
Carla Manzitti Italy
Justyna Kanold France
Evans Ae United States
Judith K. Sato United States
K. K. Matthay
Citations per year, relative to K. K. Matthay K. K. Matthay (= 1×) peers Judith K. Sato

Countries citing papers authored by K. K. Matthay

Since Specialization
Citations

This map shows the geographic impact of K. K. Matthay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. K. Matthay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. K. Matthay more than expected).

Fields of papers citing papers by K. K. Matthay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. K. Matthay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. K. Matthay. The network helps show where K. K. Matthay may publish in the future.

Co-authorship network of co-authors of K. K. Matthay

This figure shows the co-authorship network connecting the top 25 collaborators of K. K. Matthay. A scholar is included among the top collaborators of K. K. Matthay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. K. Matthay. K. K. Matthay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chesler, Louis, Susan Groshen, Roland B. Hawkins, et al.. (2011). Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study.. Journal of Clinical Oncology. 29(15_suppl). 9513–9513. 2 indexed citations
2.
London, W. B., K. K. Matthay, Peter F. Ambros, et al.. (2010). Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. Journal of Clinical Oncology. 28(15_suppl). 9518–9518. 2 indexed citations
3.
Yanik, Greg, Marguerite T. Parisi, Arlene Naranjo, et al.. (2010). MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.. Journal of Clinical Oncology. 28(15_suppl). 9516–9516. 4 indexed citations
4.
Marachelian, Araz, Min H. Kang, Judith G. Villablanca, et al.. (2009). Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. Journal of Clinical Oncology. 27(15_suppl). 10009–10009. 8 indexed citations
5.
London, W. B., John M. Maris, Hideaki Shimada, et al.. (2008). Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project. Journal of Clinical Oncology. 26(15_suppl). 10009–10009. 3 indexed citations
6.
7.
Kreissman, Susan G., Judith G. Villablanca, Lisa Diller, et al.. (2007). Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study. Journal of Clinical Oncology. 25(18_suppl). 9505–9505. 20 indexed citations
8.
Groshen, Susan, Toshiaki Ara, Yves A. DeClerck, et al.. (2007). A phase I study of zoledronic acid and low dose cyclophosphamide in children with recurrent/refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study. Journal of Clinical Oncology. 25(18_suppl). 9572–9572. 1 indexed citations
9.
Stewart, Clinton F., et al.. (2006). A topotecan-containing induction regimen for treatment of high risk neuroblastoma. Journal of Clinical Oncology. 24(18_suppl). 9013–9013. 16 indexed citations
10.
Hank, Jacquelyn A., Mark R. Albertini, Alexander Sternberg, et al.. (2004). A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of the Children's Oncology Group. Journal of Immunotherapy. 27(6). S55–S56. 3 indexed citations
11.
12.
Ma, Xiaomei, Patricia A. Buffler, Steve Selvin, et al.. (2002). Daycare attendance and risk of childhood acute lymphoblastic leukaemia. British Journal of Cancer. 86(9). 1419–1424. 95 indexed citations
13.
Blaney, Susan M., Richard L. Heideman, Stacey L. Berg, et al.. (2002). Phase I Clinical Trial of Intrathecal Topotecan in Patients With Neoplastic Meningitis. Journal of Clinical Oncology. 21(1). 143–147. 74 indexed citations
14.
Moore, Ida M., Kimberly Andrews Espy, Paul Kaufmann, et al.. (2000). Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Seminars in Oncology Nursing. 16(4). 279–290. 44 indexed citations
15.
Özkaynak, M. Fevzi, K. K. Matthay, Mitchell S. Cairo, et al.. (1998). Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.. Journal of Clinical Oncology. 16(3). 937–944. 22 indexed citations
16.
Bollen, Andrew W., et al.. (1998). Neuroblastoma in Adults and Adolescents. An Indolent Course With Poor Survival. The Journal of Urology. 159(6). 2244–2245. 41 indexed citations
17.
Villablanca, Judith G., Aamir Ali Khan, Vassilios I. Avramis, et al.. (1995). Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.. Journal of Clinical Oncology. 13(4). 894–901. 125 indexed citations
18.
Matthay, K. K., et al.. (1992). Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.. PubMed. 35(4). 244–7. 45 indexed citations
19.
McHugh, Thomas M., D. W. Wara, K. K. Matthay, et al.. (1987). Lymphocyte reconstitution in children receiving soybean agglutinin T-depleted bone marrow transplants.. PubMed. 19(1 Pt 3). 2744–2744. 6 indexed citations
20.
Moore, Sheila, C. A. Gooding, R C Brasch, et al.. (1986). Bone marrow in children with acute lymphocytic leukemia: MR relaxation times.. Radiology. 160(1). 237–240. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judith K. Sato Breakdown of academic impact, for papers by Rebecca Deyell Breakdown of academic impact, for papers by J.C. Gentet Breakdown of academic impact, for papers by M. Tezer Kutluk Breakdown of academic impact, for papers by J. M. Zucker Breakdown of academic impact, for papers by Aurora Medina‐Sansón Breakdown of academic impact, for papers by F. Breatnach Breakdown of academic impact, for papers by Carla Manzitti Breakdown of academic impact, for papers by Justyna Kanold Breakdown of academic impact, for papers by Evans Ae
Rankless by CCL
2026